Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001551 · ClinicalTrials.gov registry record
Characteristics of Idiopathic Familial Speech Disorders
A clinical trial of Stuttering and Speech Disorder, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- 375
- Enrollment target
- 2
- Study locations
NCT00001551: Completed study of Stuttering and Speech Disorder, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT00001551 is a study of Stuttering and Speech Disorder that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 375 participants, below the 713-participant average among 6 other Stuttering trials with a reported enrollment target (47% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001551, a study of Stuttering and Speech Disorder, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- 375 participants
- Enrollment target
- 2
- Study locations
Study Summary
According to studies, speech disorders with unknown causes (idiopathic) affect approximately 5% of the population at some point in their life. Some of these disorders like, stuttering and cluttering, are known for being detected early, during speech development. Stuttering is characterized by sound and syllable repetitions and consonant/vowel prolongations. When stuttering is moderate to severe, it can interfere with a person's job and social activities. Speech articulation disorders are characterized by omissions, or substitutions of speech sounds. The speech of a person who clutters is often difficult to understand. People are often unaware of the errors they make when speaking causing treatment of the condition to be very difficult. The purpose of this research is to study an extended family whose members exhibit a pure form of speech articulation disorders In addition, the study will use data and information gathered from the study and use it to develop guidelines (criteria) for defining and differentiating patients with speech disorders.
Conditions Studied
Study Locations (2)
Maryland
- University of Maryland, College Park - College Park
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 1996-05-22 |
What the finished NCT00001551 record still lists
NCT00001551 is an observational study that tracks outcomes without assigning an intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 713-participant average among 6 other Stuttering trials with a reported enrollment target (47% lower).
The record links to 3 conditions, with Stuttering appearing as the primary indexed condition, and to 0 interventions.
NCT00001551 reports a single indexed study location in Maryland, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00001551 about?
NCT00001551 is a clinical study titled "Characteristics of Idiopathic Familial Speech Disorders". According to studies, speech disorders with unknown causes (idiopathic) affect approximately 5% of the population at some point in their life. Some of these disorders like, stuttering and cluttering, are known for being detected early, during speech development. Stuttering is characterized by sound...
What is the current status of trial NCT00001551?
This trial is currently completed. The enrollment target is 375 participants. The study started on 1996-05-22.
What conditions does trial NCT00001551 study?
This clinical trial studies the following conditions: Stuttering, Speech Disorder, Developmental Articulation Disorder.
Who is sponsoring clinical trial NCT00001551?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001551 being conducted?
This trial has 2 study locations across Maryland, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stuttering
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stuttering and Neuromodulation
RECRUITING · NA
-
Exploring the Nature, Assessment and Treatment of Stuttering
RECRUITING · NA
-
The Development of Stuttering in Young Children
RECRUITING
-
Network Connectivity and Temporal Processing in Adolescents Who Stutter
RECRUITING · NA
-
Speech Processing in Stuttering
COMPLETED · NA
-
Genetic Factors Related to Stuttering
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI